Skip to main content

Advertisement

SpringerLink
Log in

The role of Chinese medicine in clinical oncology

  • Feature Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Chinese Medicine (CM) has been used for several thousand years, playing an important role in the prevention and treatment of diseases including cancer. In the recent four decades, a number of CM herbs have aroused extreme interest in the world—isolating anticancer components from medicinal herbs, using them as biological response modifiers, and most recently as angiogenesis inhibitors. The present review reports both the experimental and clinical results obtained in the field of clinical oncology, especially conducted by our group. The review also presents the possible future of integration of CM and modern medicine in basic research and clinical practice, especially when CM used as adjuvant and maintenance therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. DeVita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med 2012;366:2207–2214.

    Article  CAS  PubMed  Google Scholar 

  2. Sun Y, Yu GQ, eds. Chinese traditional medicine and Western medicine integration in the prevention and treatment of cancer. Beijing: PUMC and BMU Publishers; 1995:1–5.

    Google Scholar 

  3. Chan KL, Hussin AG, Sadikun A, Yaen KH, Asnawi MZ, Ismail Z, et al. Trends in traditional medicine research. In: Immune modulating effects of traditional Chinese medicinal herbs. Penang: The School of Pharmaceutical Sciences, University of Science Malaysia; 1995:651–660.

    Google Scholar 

  4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15–18.

    CAS  PubMed  Google Scholar 

  5. Sun Y, Wang JW, Liu Y, Song X, Zhang Y, Li K, et al. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small lung cancer (NSCLC) patients. Proc ASCO 2005;23:7138a.

    Google Scholar 

  6. Sun Y, Lin HS, Zhu RZ, Feng JF, Chen ZT, Li GS, et al. Navelbine and cysplatin combined with Rg3 and placebo in non-small cell lung cancer. Chin J Lung Cancer (Chin) 2006;9:254–258.

    Google Scholar 

  7. Huang JY, Sun Y, Fan QX, Zhang YQ. Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial. J Chin Integr Med (Chin) 2009;7:1047–1051.

    Article  Google Scholar 

  8. Sun Y. Current status in research on new anticancer drugs in China. Jpn J Chemother 2002;19:1126–1132.

    Google Scholar 

  9. Lin BJ, Zou ZH, Hua Z, Xiong SM, Peng DE, Ao ZF, et al. The effect of HOAP regimen in acute non-lymphocytic leukemia and the prognostic factors-analysis of 278 cases. Acta Acad Med Suzhou (Chin) 1985;3–4:5.

    Google Scholar 

  10. Study Group of Indirubin. Clinical study of indirubin in 314 cases of chronic myelocytic leukemia. Chin J Hematol (Chin) 1980;1:132–134.

    Google Scholar 

  11. Study Group of Meisoindigo. Cliical effect of Meisoindigo in 134 cases of chronic myelocytic leukemia. Chin J Hematol (Chin) 1988;9:135–137.

    Google Scholar 

  12. Wang ZW, et al. The extra-micro structure changes of Hydroxycamptothecine in hepatoma in ascetic mice. Chin J Oncol (Chin) 1975;1:183–185.

    Google Scholar 

  13. Ikezoe T, Chen JS, Tong XJ, Heber D, Taguchi H, Koeffler HP. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 2003:23, 1187–1193.

    CAS  PubMed  Google Scholar 

  14. Zhu LN, Yang ZJ, Wang SY, Tang Y. Kanglaite for treating advanced non-small cell Lung cancer: a systematic review. Chin J Lung Cancer (Chin) 2009;12:208–215.

    Google Scholar 

  15. Yang Y, Wang XP. Elemine anticancer and induce apoptosis. Chin J Oncol (Chin) 1996;18:169–172.

    CAS  Google Scholar 

  16. Wang JW, Zhang HP, Sun Y. Phase III clinical trial of elemenum emusion in the managment of malignant plerual and peritoneal effusions. Chin J Oncol (Chin) 1996;19:464–467.

    Google Scholar 

  17. Sun Y, Zhang YH, Yu GQ, Jiang TL, Liu JX, Chen JM, et al. Effect of Fu-zheng therapy in the management of malignant tumor patients. Chin Med J (Chin) 1981;61:97–101.

    Google Scholar 

  18. Sun Y. Chinese medicinal herbs as biological response modifiers. In: Lotzova E, Herberman RB, eds. Natural immunity against cancer and biological response modification. Basel: Karger; 1986;206–211.

    Google Scholar 

  19. Sun Y. The role of traditional Chinese medicine in supportive care of cancer patients. Resent Results Cancer Res 1986;108:327–334.

    Google Scholar 

  20. Sun Y. Clinical results of BRMs in malignant diseases. Europ J Cancer 1991;27:228.

    Article  Google Scholar 

  21. Zhou JH, Liu GZ. Recent advances in Chinese herbal drugs-action and uses. Chapter 25. Evaluation of Chinese drugs in the treatment of neoplastic diseases. Beijing & SATAS, Belgium: Science Press; 1991:236–244.

    Google Scholar 

  22. Su JZ, Guo JD, Yang LQ, Cheng PX, zhang YF, Zhang LZ. A-L Fu-zheng Granules in the management of atrophic chronic gastritis. In: Sun Y, Yu GQ, eds. Chinese traditional medicine and Western medicine integration in the prevention and treatment of cancer. Beijing: PUMC and BMU Publishers; 1995:188–192.

    Google Scholar 

  23. Sun Y, Li WL, Li LQ, Shi TZ. Immune-modulating effect of Gu-yuan Granule in 125 cancer patients. Chin J New Drugs (Chin) 1996;5:29–32.

    Google Scholar 

  24. Jia JW, Liu YQ. The effect of Shenqi Fuzheng Injection combined with FOLFOX4 regimen in the treatment of advanced gastric cancer. J Pract Oncol (Chin) 2009;24:273–275.

    Google Scholar 

  25. Sun Y, Yuan RR, Li WL, Li LQ, Shi TZ, Su M, et al. Immune-modulating effect of Lugastrin-results of a double blind clinical phase II trial. Chin J Clin Pharmacol (Chin) 1990;6:72–75.

    Google Scholar 

  26. Sun Y, Hersh EM, Lee SL, McLaughlin M, Loo TL, Mavligit GM. Preliminary observations on the effects of Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on Lymphocytes blastogenic responses. J Biol Response Modif 1983;2:227–237.

    CAS  Google Scholar 

  27. Sun Y, Hersh EM, Talpaz M, Lee SL, Wong W, Loo TL, et al. Immune restoration and/or angmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer 1983;52:70–73.

    Article  CAS  PubMed  Google Scholar 

  28. Hou YD, Ma GL, Wu SH, Li YY, Li HT. Effects of Radix Astragali seu hedysari on the interferon system. Chin Med J 1981;94:35–40.

    CAS  PubMed  Google Scholar 

  29. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus mambranaceus, a Chinese medicinal herbs, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol 1988;26:183–187.

    CAS  PubMed  Google Scholar 

  30. Sun Y, Hong Wj, Deng J, Liu D, Feng ZK, Yin WB, et al. Observation on 10 year follow-up of cancer patients with Fu-zheng therapy. J Integr Tradit Chin Med West Med (Chin) 1987;7:712–714.

    CAS  Google Scholar 

  31. Zhang ZX, Zhou QH. Advances of the traditional Chinese medicine in antiangiogenic therapy of tumors. Chin J Lung Cancer (Chin) 2005;9:96–99.

    CAS  Google Scholar 

  32. Sun Y. Angiogenesis inhibitors as clinical targeted therapy. Cancer Res Prog; 2006;4:1–5

    Google Scholar 

  33. Zhao Y, Liu JW. Research progress of anticancer effects of 20 (R)-Gensinoside Rg3. J Clin Oncol (Chin) 2001;6:81–82.

    CAS  Google Scholar 

  34. Pang H, Wang HL, Fu L, Su CY. Human phamaco-kenetic study of Rg3. Acta Pharmacuetica Sinica 2001;36:170–173.

    CAS  Google Scholar 

  35. Li PP. Could we use clinical benefit to evaluate the effects of Chinese medicine on the treatment of cancer? Chin J Integr Med 2010;16:9–10.

    Article  CAS  PubMed  Google Scholar 

  36. Cutler DM. The next wave of corporate medicine—how we all might benefit? N Engl J Med 2009;361:549–551.

    Article  CAS  PubMed  Google Scholar 

  37. You J. The application of assessment of the quality of life in the clinical efficacy evaluation system and the selection of questionnaires of Chinese medicine treating tumors. Chin J Integr Med 2010;16:11–12.

    Article  PubMed  Google Scholar 

  38. Yang YF. Exploration of key points in evaluation criteria of Chinese medicine in the treatment of cancer. Chin J Integr Med 2010;16:3–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, 100210, China

    Yan Sun  (孙 燕)

Authors
  1. Yan Sun  (孙 燕)
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sun, Y. The role of Chinese medicine in clinical oncology. Chin. J. Integr. Med. 20, 3–10 (2014). https://doi.org/10.1007/s11655-013-1551-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-013-1551-2

Keywords

Search

Navigation